BioMarin Pharmaceuticals
BMRN
576 hedge funds and large institutions have $9.72B invested in BioMarin Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 226 increasing their positions, 200 reducing their positions, and 74 closing their positions.
53% more call options, than puts
Call options by funds: $91M | Put options by funds: $59.3M
13% more repeat investments, than reductions
Existing positions increased: 226 | Existing positions reduced: 200
1% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 74
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
1% less funds holding
Funds holding: 581 → 576 (-5)
4% less capital invested
Capital invested by funds: $10.1B → $9.72B (-$419M)
2.69% less ownership
Funds ownership: 96.18% → 93.49% (-2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$123M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
+$60.3M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$51.8M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$46.5M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$38.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$227M |
| 2 |
BlackRock
New York
|
-$112M |
| 3 |
Morgan Stanley
New York
|
-$59.9M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$53.3M |
| 5 |
D.E. Shaw & Co
New York
|
-$48M |
BMRN Hedge Fund Activity: Q3 2025 in Review
576 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2025, worth a combined $9.72B — down 4.1% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new BMRN positions and 74 closed out — a net gain of 1 holder — while 226 added to existing stakes and 200 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $123M. The largest seller was Viking Global Investors, cutting an estimated $227M.
- 576 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2025, down from 581 in Q2 2025.
- Funds reported $9.72B of BioMarin Pharmaceuticals stock for Q3 2025, down 4.1% quarter-over-quarter.
- 75 funds opened new BioMarin Pharmaceuticals positions in Q3 2025 and 74 closed out, a net change of +1 holder.
- The largest BioMarin Pharmaceuticals buyer in Q3 2025 was Capital Research Global Investors, an estimated $123M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2025 was Viking Global Investors, an estimated $227M sold.
Based on aggregated 13F filings for Q3 2025.